Results 141 to 150 of about 13,611 (195)

Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II. [PDF]

Synapse, 2009
Han L, Picker JD, Schaevitz LR, Tsai G, Feng J, Jiang Z, Chu HC, Basu AC, Berger-Sweeney J, Coyle JT.   +9 more
europepmc   +1 more source

Activation of the Pancreatic "Metabolic Synapse" Aggravates Type 2 Diabetes Mellitus by Inducing PANoptosis in β-Cells. [PDF]

Diabetes
Xiang Z, Zitian L, Guangwei Y, Shuohui D, Kexin W.   +4 more
europepmc   +1 more source

How a Medicinal Chemistry Project Changed the Way Prostate Cancer is Diagnosed and Treated. [PDF]

J Med Chem
Kozikowski AP, Neale J.
europepmc   +1 more source

Cost-Effectiveness of PSMA PET/CT as Single Procedure for Diagnosis and Staging High-Grade Prostate Cancer: A Single Center Experience. [PDF]

In Vivo
Pepe P, Pepe L, Pepe G, Privitera R.
europepmc   +1 more source

Optimizing PSMA-617-based inhibitors through charged linker modifications: Insights into structure-activity relationships. [PDF]

Theranostics
Geis NM, Braunwarth Y, Meyer PT, Eder M, Eder AC.   +4 more
europepmc   +1 more source

Isolation of tubulin polyglutamylase from Crithidia; binding to microtubules and tubulin, and glutamylation of mammalian brain α- and β- tubulins.

, 1999
Horn, E., Schneider, A., Weber, K., Westermann, S.   +3 more
core  

Some of the next articles are maybe not open access.

Related searches:

Enantiospecificity of Glutamate Carboxypeptidase II Inhibition

Journal of Medicinal Chemistry, 2005
Two representative glutamate carboxypeptidase II (GCP II) inhibitors, 2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid 2 and 2-(3-mercaptopropyl)pentanedioic acid 3, were synthesized in high optical purities (>97%ee). The two enantiomers of 2 were prepared from previously reported chiral intermediates, (R)- and (S)-2 ...
Takashi, Tsukamoto, Pavel, Majer, Dilrukshi, Vitharana, Chiyou, Ni, Bunda, Hin, Xi-Chun M, Lu, Ajit G, Thomas, Krystyna M, Wozniak, David C, Calvin, Ying, Wu, Barbara S, Slusher, David, Scarpetti, George W, Bonneville   +12 more
openaire   +2 more sources

Expression of glutamate carboxypeptidase II in human brain

Neuroscience, 2007
Glutamate carboxypeptidase II (GCPII) is a transmembrane glycoprotein expressed in various tissues. When expressed in the brain it cleaves the neurotransmitter N-acetylaspartylglutamate (NAAG), yielding free glutamate. In jejunum it hydrolyzes folylpoly-gamma-glutamate, thus facilitating folate absorption.
P, Sácha, J, Zámecník, C, Barinka, K, Hlouchová, A, Vícha, P, Mlcochová, I, Hilgert, T, Eckschlager, J, Konvalinka   +8 more
openaire   +2 more sources

Inhibition of Glutamate Carboxypeptidase II by Phosphonamidothionate Derivatives of Glutamic Acid

Journal of Enzyme Inhibition, 2001
A limited series of N-thiophosphonyl-glutamates were found to be inhibitors of the prostate-specific membrane antigen (PSMA) form of glutamate carboxypeptidase II. Comparative inhibitory profiles of an analogous O-thiophosphonyl-2-hydroxyglutarate revealed that the amido-linkage of the N-thiophosphonyl-glutamate provides a significant enhancement of ...
Rodriguez, Chester E, Lu, Haiyan, Martinez, Alicia R, Hu, Ying, Brunelle, Alan, Berkman, Clifford E   +5 more
openaire   +3 more sources

Structure-Activity Relationships of Glutamate Carboxypeptidase II (GCPII) Inhibitors

Current Medicinal Chemistry, 2012
Glutamate carboxypeptidase II (GCPII, EC 3.4.17.21) is a zinc metallopeptidase that hydrolyzes N-acetylaspartylglutamate (NAAG) into N-acetylaspartate (NAA) and glutamate in the nervous system. Inhibition of GCPII has the potential to reduce extracellular glutamate and represents an opportune target for treating neurological disorders in which excess ...
D V, Ferraris, K, Shukla, T, Tsukamoto
openaire   +2 more sources